FY2025 EPS Estimates for ESPR Lifted by Cantor Fitzgerald

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Esperion Therapeutics in a report issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings of $0.12 per share for the year, up from their prior estimate of $0.05. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

ESPR has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $1.50 on Friday. The firm’s 50-day moving average price is $1.89 and its 200-day moving average price is $2.08. The firm has a market capitalization of $296.77 million, a price-to-earnings ratio of -2.34 and a beta of 1.04. Esperion Therapeutics has a 1-year low of $1.47 and a 1-year high of $3.94.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ESPR. Cibc World Markets Corp purchased a new position in Esperion Therapeutics in the fourth quarter worth about $39,000. Versor Investments LP purchased a new position in Esperion Therapeutics in the third quarter worth about $44,000. SJS Investment Consulting Inc. purchased a new position in Esperion Therapeutics in the fourth quarter worth about $55,000. Crestline Management LP purchased a new position in Esperion Therapeutics in the fourth quarter worth about $63,000. Finally, Summit Wealth Group LLC purchased a new position in Esperion Therapeutics in the third quarter worth about $66,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.